September 2024
1. PERROTT SL, Kar SP
   Polygenic risk scores for genomics and population screening.
   Lancet. 2024;404:935-936.
   

   >> Share

   
   March 2024
2. NARUSE M, Young WF Jr
   Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma.
   Lancet. 2024;403:1001-1003.
   

   >> Share

   
   February 2024
3. TURNBULL C, Firth HV, Wilkie AOM, Newman W, et al
   Population screening requires robust evidence-genomics is no exception.
   Lancet. 2024;403:583-586.
   

   >> Share

   
   July 2023
4. THE LANCET
   Genomic newborn screening: current concerns and challenges.
   Lancet. 2023;402:265.
   

   >> Share

   
   June 2023
5. SWEN JJ, Manson LEN, Bohringer S, Pirmohamed M, et al
   The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors' reply.
   Lancet. 2023;401:1851-1852.
   

   >> Share

   
   
6. VAN DER LINDEN L
   The PREPARE study: benefits of pharmacogenetic testing are unclear.
   Lancet. 2023;401:1851.
   

   >> Share

   
   
7. ROGERS A, Mackenzie IS, MacDonald TM, Doney ASF, et al
   The PREPARE study: benefits of pharmacogenetic testing are unclear.
   Lancet. 2023;401:1850.
   

   >> Share

   
   
8. CURTIS D
   The PREPARE study: benefits of pharmacogenetic testing are unclear.
   Lancet. 2023;401:1850-1851.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share